Immutep Ltd (IMMP) Options

IMMP under $2

Refinitiv Logo
As of 06/27/2024

SellUnderperformHoldOutperformSelected Value:Buy
Refinitiv Stock Reports Plus
Refinitiv maintains a current price target of $8.64 for IMMP.

IMMP......................https://stockcharts.com/h-sc/ui?s=IMMP&p=W&b=5&g=0&id=p86431144783

IMMP under $2

IMMP under $3

IMMP under $2

nice

nice

nice

strong

nice

ready

nice

strong

watching

watching

dip

dip

nice

im in my bio DRMA, one at a time


RIGL rip for more

beast

IMMP +65% on interim (single-arm) phase-2 data for LAG-3 drug with Keytruda in NSCLC:

https://finance.yahoo.com/news/immutep-efti-combination-pembrolizumab-achieves-120000596.html

IMMP’s eftilagimod alpha is a LAG-3 protein that targets the same biologic pathway as BMY’s relatlimab, one of the component drugs (along with Opdivo) in Opdulag.

BMY’s Opdulag, which was FDA approved in Mar 2022 for first-line melanoma, is already selling at an annualized rate of $500M in the US alone (#msg-171784010).

Please see #msg-168259768 for related info.

IMMP: Very likely the hands-down WINNER of this Wall Street day, Peeps!!! (Just when ya thought that CANCER was no longer TRENDING.)

Going to move up

It's cool covered most average was $3.68

I think you're not taking into account whats in the pipeline mainly several studies involving much larger pharmaceutical interested the immune boosting properties of eftaligamod. Imo this company and ceo are the real deal. Forget the outlays and remember its research and development that costs the most up front no matter what pharm you're talking about

More debt than revenue, large negatives on everything (cash flow, returns and profit margins.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 6.35M
Revenue Per Share (ttm) 0.14
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -17.07M
Net Income Avi to Common (ttm) -27.36M
Diluted EPS (ttm) -0.4500

Total Debt (mrq) 9.75M
Book Value Per Share (mrq) 0.94

Cash Flow Statement
Operating Cash Flow (ttm) -14.67M
Levered Free Cash Flow (ttm) -7.67M

IMMP Interesting action....

* * $IMMP Video Chart 04-08-2021 * *

Link to Video - click here to watch the technical chart video

Any positives in the numbers? Decent news but will need to raise money to keep anything going imho

IMMP is "ELIGIBLE" to receive development based milestones and sales based royalties. They do not have sales and drug is not out.


Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 4.85M
Revenue Per Share (ttm) 0.11
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -13.03M
Net Income Avi to Common (ttm) -20.89M
Diluted EPS (ttm) -0.4600

Balance Sheet
Total Cash Per Share (mrq) 0.65 will blow through it and need a serious capital raise imho
Total Debt (mrq) 7.45M
Book Value Per Share (mrq) 0.71

Cash Flow Statement
Operating Cash Flow (ttm) -11.2M
Levered Free Cash Flow (ttm) -5.86M

Had R/S a couple years ago and was $0.53 about a year ago

Quarterly growth -76.9%, returns are negative, zero profit and cash flow is very negative.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 4.85M
Revenue Per Share (ttm) 0.11
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -13.03M
Net Income Avi to Common (ttm) -20.89M
Diluted EPS (ttm) -0.4600

Balance Sheet
Total Cash Per Share (mrq) 0.65
Total Debt (mrq) 7.45M
Book Value Per Share (mrq) 0.71

Cash Flow Statement
Operating Cash Flow (ttm) -11.2M
Levered Free Cash Flow (ttm) -5.86M

I agree it states that Novartis is in chagre and IMMP is "ELIGIBLE" to receive milestones and payments. Previous reverse split. IMHO prob going to be bled

IMMP never holds any spikes. Every time it has fastrack or patent news it dumps away. It is the real deal to dump very hard. GLTA!

This is the real deal folks

* * $IMMP Video Chart 03-25-2021 * *

Link to Video - click here to watch the technical chart video

IMMP up on BMY's LAG-3 coattails: #msg-162784750.

And they have a very sharp ceo if you've seen any of their videos he tells it straight up imo

Up huge on no news a great big sleeper imo

Looks like accumulation is beginning a slow churn higher

Interesting company, looks to be in reversal but dip opportunity may be in the works.

Like it here

$IMMP: TIPRANKS, SCORE, UPGRADE TO 10 OUTPERFORM! ANALIST RATINGS: PT: $6.50 MODERATE BUY! LOW: @5.50, MED:@6.50, HI: $8.00 Jason McCarthy Maxim Group 5 Stars target $8.00 ranking Buy analystAction Reiterated date 6 days ago Last calification.